Ruby J. Siegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruby J. Siegel has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Andrés Jaramillo
Department of Laboratory Medicine and Pathology Mayo Clinic Phoenix Arizona USA
9 shared publications - Katrin Hacke
Department of Laboratory Medicine and Pathology Mayo Clinic Phoenix Arizona USA
9 shared publications Rose M. Ridgley
Department of Laboratory Medicine and Pathology Mayo Clinic Phoenix Arizona USA
7 shared publicationsDanielle M. Troop
Department of Laboratory Medicine and Pathology Mayo Clinic Phoenix Arizona USA
5 shared publications- Brian J. Franz
Department of Laboratory Medicine and Pathology Mayo Clinic Phoenix Arizona USA
2 shared publications - Catherine L. Gebhart
Department of Laboratory Medicine and Pathology Mayo Clinic Phoenix Arizona USA
2 shared publications
Latest Publications
Identification of the Novel HLA‐DRB1*03:234 Allele by Next‐Generation Sequencing
HLA‐DRB1*03:234 differs from HLA‐DRB1*03:01:01:01 by two adjacent nucleotide substitutions in exon 2.
Identification of the Novel HLA‐DRB1*03:234 Allele by Next‐Generation Sequencing
HLA‐DRB1*03:234 differs from HLA‐DRB1*03:01:01:01 by two adjacent nucleotide substitutions in exon 2.
Identification of the Novel HLA‐C*07:1268 Allele by Next‐Generation Sequencing
HLA‐C*07:1268 differs from HLA‐C*07:02:01:01 by one nucleotide substitution in exon 3.
Identification of the Novel HLA‐C*07:1268 Allele by Next‐Generation Sequencing
HLA‐C*07:1268 differs from HLA‐C*07:02:01:01 by one nucleotide substitution in exon 3.
Identification of the Novel HLA‐B*08:345Q Allele by Next‐Generation Sequencing
HLA‐B*08:345Q differs from HLA‐B*08:238 by one nucleotide substitution, introducing a premature stop codon in exon 5.
Identification of the Novel HLA‐B*08:345Q Allele by Next‐Generation Sequencing
HLA‐B*08:345Q differs from HLA‐B*08:238 by one nucleotide substitution, introducing a premature stop codon in exon 5.
Identification of the Novel HLA ‐A*32:202 Allele by Next‐Generation Sequencing and Oxford Nanopore Sequencing
HLA‐A*32:202 differs from HLA‐A*32:01:01:01 by two nucleotide substitutions in exons 1 and 2.
Identification of the Novel HLA ‐A*32:202 Allele by Next‐Generation Sequencing and Oxford Nanopore Sequencing
HLA‐A*32:202 differs from HLA‐A*32:01:01:01 by two nucleotide substitutions in exons 1 and 2.
Identification of the Novel HLA‐B*57:205 Allele by Next‐Generation Sequencing
HLA‐B*57:205 differs from HLA‐B*57:01:01:01 by one nucleotide substitution in Exon 1.
Identification of the Novel HLA‐B*57:205 Allele by Next‐Generation Sequencing
HLA‐B*57:205 differs from HLA‐B*57:01:01:01 by one nucleotide substitution in Exon 1.
Identification of the HLA‐DQB1*06:144N Allele by Next‐Generation Sequencing
HLA‐DQB1*06:144N differs from HLA‐DQB1*06:03:01:01 by one nucleotide substitution, introducing a premature stop codon in exon 2.
Identification of the HLA‐DQB1*06:144N Allele by Next‐Generation Sequencing
HLA‐DQB1*06:144N differs from HLA‐DQB1*06:03:01:01 by one nucleotide substitution, introducing a premature stop codon in exon 2.
Identification of the Novel HLA‐A*24:675 Allele by Next‐Generation Sequencing
HLA‐A*24:675 differs from HLA‐A*24:02:01:01 by one nucleotide substitution in exon 3.
Identification of the Novel HLA‐A*24:675 Allele by Next‐Generation Sequencing
HLA‐A*24:675 differs from HLA‐A*24:02:01:01 by one nucleotide substitution in exon 3.
Identification of the Novel HLA‐DQB1*06:549 Allele by Next‐Generation Sequencing
HLA‐DQB1*06:549 differs from HLA‐DQB1*06:02:01:01 by one nucleotide substitution in exon 2.
Identification of the Novel HLA‐DQB1*06:549 Allele by Next‐Generation Sequencing
HLA‐DQB1*06:549 differs from HLA‐DQB1*06:02:01:01 by one nucleotide substitution in exon 2.
Identification of the Novel HLA‐C*03:737 Allele by Next‐Generation Sequencing
HLA‐C*03:737 differs from HLA‐C*03:05:01:01 by one nucleotide substitution in exon 3.
Identification of the Novel HLA‐C*03:737 Allele by Next‐Generation Sequencing
HLA‐C*03:737 differs from HLA‐C*03:05:01:01 by one nucleotide substitution in exon 3.
- Open Access
- 26 December 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (3) , 347-360
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant
Significance Statement: There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted for desensitization to deplete plasma cells producing alloantibodies and donor-specific antibodies. Few studies and case reports are available regarding the use of CD38 antibodies for desensitization in patients awaiting kidney transplant. This study shows that isatuximab, a CD38-targeting therapy, was well tolerated in kidney transplant candidates, with a durable decrease in anti-HLA antibodies and partial desensitization activity. The short treatment period and long follow-up of this study allowed for the understanding of the mechanism and timing for any antibody rebound. Isatuximab could be further investigated as an option for adjunct therapy to existing desensitization for patients on the kidney transplant waitlist. Background: Patients with calculated panel reactive antibody (cPRA) ≥80.00%, particularly those with cPRA ≥99.90%, are considered highly sensitized and underserved by the Kidney Allocation System. Desensitization removes circulating reactive antibodies and/or suppresses antibody production to increase the chances of a negative crossmatch. CD38 is expressed highly on plasma cells, thus is a potential target for desensitization. Methods: This was an open-label single-arm phase 1/2 study investigating the safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantation. There were two cohorts, cohorts A and B, which enrolled cPRA ≥99.90% and 80.00% to + plasmablasts, plasma cells, and NK cells and significant reductions in HLA-specific IgG-producing memory B cells. Overall response rate, on the basis of a predefined composite desensitization end point, was 83.3% and 81.8% in cohorts A and B. Most responders had decreases in anti-HLA antibodies that were maintained for 26 weeks after the last dose. Overall, cPRA values were minimally affected, however, with only 9/23 patients (39%) having cPRA decreases to target levels. By study cutoff (median follow-up of 68 weeks), six patients received transplant offers, of which four were accepted. Conclusions: In this open-label trial, isatuximab was well tolerated and resulted in a durable decrease in anti-HLA antibodies with partial desensitization activity. Clinical Trial registration number: NCT04294459.
- 26 December 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (3) , 347-360
Open AccessIsatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant
Significance Statement: There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted for desensitization to deplete plasma cells producing alloantibodies and donor-specific antibodies. Few studies and case reports are available regarding the use of CD38 antibodies for desensitization in patients awaiting kidney transplant. This study shows that isatuximab, a CD38-targeting therapy, was well tolerated in kidney transplant candidates, with a durable decrease in anti-HLA antibodies and partial desensitization activity. The short treatment period and long follow-up of this study allowed for the understanding of the mechanism and timing for any antibody rebound. Isatuximab could be further investigated as an option for adjunct therapy to existing desensitization for patients on the kidney transplant waitlist. Background: Patients with calculated panel reactive antibody (cPRA) ≥80.00%, particularly those with cPRA ≥99.90%, are considered highly sensitized and underserved by the Kidney Allocation System. Desensitization removes circulating reactive antibodies and/or suppresses antibody production to increase the chances of a negative crossmatch. CD38 is expressed highly on plasma cells, thus is a potential target for desensitization. Methods: This was an open-label single-arm phase 1/2 study investigating the safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantation. There were two cohorts, cohorts A and B, which enrolled cPRA ≥99.90% and 80.00% to + plasmablasts, plasma cells, and NK cells and significant reductions in HLA-specific IgG-producing memory B cells. Overall response rate, on the basis of a predefined composite desensitization end point, was 83.3% and 81.8% in cohorts A and B. Most responders had decreases in anti-HLA antibodies that were maintained for 26 weeks after the last dose. Overall, cPRA values were minimally affected, however, with only 9/23 patients (39%) having cPRA decreases to target levels. By study cutoff (median follow-up of 68 weeks), six patients received transplant offers, of which four were accepted. Conclusions: In this open-label trial, isatuximab was well tolerated and resulted in a durable decrease in anti-HLA antibodies with partial desensitization activity. Clinical Trial registration number: NCT04294459.